Condition: Advanced Solid Tumors · MSI-H or dMMR Advanced Solid Tumors · MSI-H/dMMR Gastric Cancer · Sponsor: Eikon Therapeutics
The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.
This description comes directly from the study's public registry record.
Ana C Mamede, PharmD · 347-806-4584 · mamedea@eikontx.com
Krishna Kaza · kazak@eikontx.com
Always discuss trial participation with your own doctor first.
| Morristown Medical Center | Morristown, New Jersey, United States | Not Yet Recruiting |
| Memorial Sloan Kettering Cancer Center (MSKCC) | New York, New York, United States | Not Yet Recruiting |
| University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| GenesisCare North Shore (Oncology) | Saint Leonards, New South Wales, Australia | Not Yet Recruiting |
| Calvary Mater Newcastle Hospital | Waratah, New South Wales, Australia | Recruiting |
| Grampians Health | Ballarat, Victoria, Australia | Recruiting |
| Chris O'Brien Lifehouse (Sydney Cancer Centre) | Camperdown, Victoria, Australia | Recruiting |
| Oncology Clinics Victoria (OCV) - Cabrini Brighton Hospital | Frankston, Victoria, Australia | Not Yet Recruiting |
| Peninsula and Southeast Oncology (PASO) Medical | Frankston, Victoria, Australia | Recruiting |
| Health New Zealand | Wellington, New Zealand | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07262619